Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 75.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 25,311 shares of the company's stock after selling 77,043 shares during the period. Russell Investments Group Ltd.'s holdings in Elanco Animal Health were worth $307,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hillsdale Investment Management Inc. lifted its holdings in Elanco Animal Health by 2.1% in the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock worth $524,000 after purchasing an additional 900 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Elanco Animal Health by 0.8% in the 4th quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock worth $1,737,000 after purchasing an additional 1,166 shares during the period. MTM Investment Management LLC boosted its stake in Elanco Animal Health by 9.3% during the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock worth $172,000 after buying an additional 1,200 shares during the period. Blue Trust Inc. raised its position in Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after purchasing an additional 1,894 shares during the period. Finally, Jones Financial Companies Lllp lifted its stake in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.89% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ELAN shares. Barclays decreased their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Morgan Stanley lowered their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. UBS Group cut their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Finally, Stifel Nicolaus reduced their price objective on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $14.67.

Elanco Animal Health Trading Down 2.7 %

Shares of ELAN stock traded down $0.26 during trading hours on Wednesday, hitting $9.48. The company had a trading volume of 4,288,947 shares, compared to its average volume of 4,943,932. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company's fifty day moving average is $9.94 and its 200 day moving average is $11.56. The stock has a market capitalization of $4.71 billion, a PE ratio of 23.70, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the firm earned $0.08 earnings per share. The business's revenue was down 1.4% compared to the same quarter last year. Research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.